What Can You Expect in 2026?
Join a global community of DDR experts in Boston to explore the next frontier of targeted oncology. From validating novel DDR targets and refining biomarker-driven patient selection to integrating DDR inhibitors with ADCs, radiotherapy, and chemotherapy, this summit delivers actionable insights across discovery, translational science, and clinical development.
Expect high-impact case studies, strategic panels, and interactive roundtables designed to help you overcome resistance, improve safety, and fast-track your DDR pipeline. Whether you're a biotech innovator, academic researcher, or pharma leader, this is your must-attend meeting to drive progress in DDR therapeutics.
Unmissable Event Highlights:
Biomarker Breakthroughs
The DDR field is entering a new era of precision medicine. Hear from EMD Serono, Step Pharma, and the University of Pennsylvania as they unveil cutting-edge predictive and functional biomarkers that are transforming patient selection, optimizing dosing strategies, and unlocking smarter combination therapies.
Smarter Combinations Strategies
Resistance remains one of the biggest hurdles in DDR drug development. Learn how Artios Pharma, VSPharmTech, CrossBridge Bio and The University of Glasgow are pioneering innovative approaches to combine DDR inhibitors with radiotherapy, chemotherapy, ADCs, oncolytic viruses and radiopharmaceuticals, delivering more durable responses and expanding therapeutic windows.
Expanding the DDR Target Space
Beyond PARP lies a world of untapped opportunity. Explore breakthrough data on emerging targets such as ATR, CHK1/2, DNA-PK, WEE1, Polθ, ALC1 and DHX9 from the University of Oxford, Accent Therapeutics, Breakpoint Therapeutics and MD Anderson Cancer Center. Discover how these novel mechanisms are redefining synthetic lethality and shaping the next generation of DDR therapeutics
What’s New for 2026
Biotech Innovation & Academic to Industry Collaboration
Hear from Rakovina Therapeutics, Modifi Bio & Breakpoint Therapeutics on translating DDR discoveries into biotech ventures.
Focus on Translational Bottlenecks
Explore clinical setbacks and the reasons promising DDR targets fail with Merck, Roche, Mayo Clinic, EMD Serono and the Dana-Farber Cancer Institute.
Novel Modalities
Sessions on dual-payload ADCs, DDR-targeting antibodies, and synthetic lethality beyond PARP.
Explore the Full Event Guide
- 30+ expert speakers from leading biopharma, biotech, and academia
- 3 days of exclusive content, including a dedicated Biomarker Focus Day
- 80+ attendees focused exclusively on DDR-targeted drug development
- 1 Scientific Poster Session to showcase your latest research
- Unmissable sessions on enhancing patient stratification, optimizing combination strategies & overcoming resistance
Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join DDR Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.